News

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation.

07/28/2025

Qualigen Granted New Patents Covering 25 Countries

CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalene Diimides and Their Use.” The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing.

07/16/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Qualigen Therapeutics, Inc. (QLGN) a buy, sell, or hold?

Qualigen Therapeutics, Inc. (QLGN) can sell. Click on Rating Page for detail.

What is Qualigen Therapeutics, Inc.'s stock price?

The price of Qualigen Therapeutics, Inc. (QLGN) is 2.25 and it was updated on 2025-09-17 13:00:26.

Is Qualigen Therapeutics, Inc. (QLGN) overvalued or undervalued?

Currently Qualigen Therapeutics, Inc. (QLGN) is in overvalued.

News

From:

To:

News
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. Mon, May. 19, 2025
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the “Listing Rule”) as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024 (the “2024 Form 10-K”), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the “Form 12b-25”) filed with the Securities and Exchange Commission (the "SEC") on April 1, 2025. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. Thu, May. 01, 2025
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations. Mon, Nov. 25, 2024
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301. Fri, Nov. 01, 2024
Qualigen Therapeutics, Inc. Announces management changes. CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. Thu, Sep. 26, 2024

Transcripts

Transcipts Data
Qualigen Therapeutics, Inc. (QLGN) on Q1 2021 Results - Earnings Call Transcript SA Transcripts Tue, Aug. 18, 2020

SEC Filings

SEC Filings
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/27/2025
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/14/2025
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 08/13/2025
Qualigen Therapeutics, Inc. (QLGN) - SCHEDULE 13G/A SEC Filings 08/07/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/28/2025
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 07/21/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/16/2025
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 06/30/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/24/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/19/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/01/2025
Qualigen Therapeutics, Inc. (QLGN) - NT 10-K - Current report SEC Filings 04/01/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/28/2025
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/26/2024
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 12/20/2024
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 12/09/2024
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 11/22/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K/A - Current report SEC Filings 11/21/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/21/2024
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 11/15/2024
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/14/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/13/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/08/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/01/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/29/2024
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 10/24/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/22/2024
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 10/17/2024
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 10/09/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/09/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/26/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/20/2024
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 09/10/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/09/2024
Qualigen Therapeutics, Inc. (QLGN) - 424B4 SEC Filings 09/06/2024
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 09/05/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/05/2024
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 08/22/2024
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/14/2024
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 08/09/2024
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 08/09/2024
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 08/07/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/05/2024
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 07/25/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/18/2024
Qualigen Therapeutics, Inc. (QLGN) - PRE 14A SEC Filings 07/16/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/15/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/11/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 02/27/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 02/22/2024
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/07/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/22/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/14/2023
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/14/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/08/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/17/2023
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 10/03/2023
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 09/29/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/28/2023
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 09/08/2023
Qualigen Therapeutics, Inc. (QLGN) - POS AM SEC Filings 09/01/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/15/2023
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/04/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/01/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/26/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/13/2023
Qualigen Therapeutics, Inc. (QLGN) - 10-K/A - Current report SEC Filings 07/07/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/26/2023
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 06/13/2023
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 06/02/2023
Qualigen Therapeutics, Inc. (QLGN) - ARS SEC Filings 06/02/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/19/2023
Qualigen Therapeutics, Inc. (QLGN) - PRE 14A SEC Filings 05/15/2023
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/15/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/05/2023
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 05/02/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 04/24/2023
Qualigen Therapeutics, Inc. (QLGN) - NT 10-K - Current report SEC Filings 03/31/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 02/13/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/20/2023
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/10/2023
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 01/06/2023
Qualigen Therapeutics, Inc. (QLGN) - S-3 SEC Filings 12/30/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/22/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/12/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/22/2022
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/28/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/26/2022
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 09/28/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/02/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/26/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/16/2022
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/15/2022
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 08/08/2022
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 08/08/2022
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 08/04/2022
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 08/03/2022
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 08/03/2022
Qualigen Therapeutics, Inc. (QLGN) - DEL AM SEC Filings 08/01/2022
Qualigen Therapeutics, Inc. (QLGN) - S-3 SEC Filings 07/29/2022
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 07/13/2022
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 07/13/2022
Qualigen Therapeutics, Inc. (QLGN) - PRE 14A SEC Filings 07/01/2022
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 06/30/2022
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 06/30/2022
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 06/27/2022
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 06/24/2022
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 06/22/2022
Qualigen Therapeutics, Inc. (QLGN) - S-3 SEC Filings 06/17/2022
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 06/15/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/02/2022
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 05/27/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/13/2022
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/13/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/04/2022
Qualigen Therapeutics, Inc. (QLGN) - 10-K/A - Current report SEC Filings 04/29/2022
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 03/31/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/04/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/18/2022
Qualigen Therapeutics, Inc. (QLGN) - S-8 SEC Filings 01/10/2022
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 01/05/2022
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/17/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/10/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 12/10/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K/A - Current report SEC Filings 12/09/2021
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 12/06/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/01/2021
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 12/01/2021
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/15/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 08/20/2021
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/16/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/13/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 05/18/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/17/2021
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 05/17/2021
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/14/2021
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 04/29/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 04/26/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 04/21/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 04/19/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 04/09/2021
Qualigen Therapeutics, Inc. (QLGN) - 10-KT - Current report SEC Filings 03/31/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/05/2021
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/06/2021
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 12/30/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 12/29/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/18/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 12/18/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/08/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 12/08/2020
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 12/07/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 11/23/2020
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/12/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/03/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/09/2020
Qualigen Therapeutics, Inc. (QLGN) - S-8 SEC Filings 10/02/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/02/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 10/02/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 08/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 08/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/14/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 08/05/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/04/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 08/04/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/10/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 07/10/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/09/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K/A - Current report SEC Filings 06/29/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/11/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 06/08/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K/A - Current report SEC Filings 06/03/2020
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 06/01/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/29/2020
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 05/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 05/27/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 05/27/2020
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 05/27/2020
Qualigen Therapeutics, Inc. (QLGN) - S-4MEF SEC Filings 05/20/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/19/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/19/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 05/19/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/14/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/14/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 05/14/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/11/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/11/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/08/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/06/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/05/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/01/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 05/01/2020
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/01/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 04/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 10-K/A - Current report SEC Filings 04/24/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 04/23/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 04/21/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 04/16/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 04/16/2020
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 04/10/2020
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 04/09/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 04/09/2020
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 04/07/2020
Qualigen Therapeutics, Inc. (QLGN) - S-4/A SEC Filings 04/06/2020
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 04/06/2020
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 04/02/2020
Qualigen Therapeutics, Inc. (QLGN) - NT 10-K - Current report SEC Filings 03/31/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/31/2020
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 03/31/2020
Qualigen Therapeutics, Inc. (QLGN) - S-4/A SEC Filings 03/27/2020
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 03/27/2020
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 03/24/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 03/16/2020
Qualigen Therapeutics, Inc. (QLGN) - S-4/A SEC Filings 03/13/2020
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 03/13/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 03/13/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/11/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 03/11/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/03/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 03/03/2020
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 03/03/2020
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 02/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 02/27/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 02/21/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 02/21/2020
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/14/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 02/07/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 02/07/2020
Qualigen Therapeutics, Inc. (QLGN) - S-4 SEC Filings 02/04/2020
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 01/29/2020
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 01/28/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/21/2020
Qualigen Therapeutics, Inc. (QLGN) - 425 SEC Filings 01/21/2020
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 01/17/2020
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/26/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/14/2019
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/14/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/07/2019
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 11/07/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/01/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/15/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/18/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/12/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/23/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/14/2019
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/14/2019
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 08/06/2019
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 08/02/2019
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 08/02/2019
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 07/30/2019
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 07/29/2019
Qualigen Therapeutics, Inc. (QLGN) - S-3 SEC Filings 07/24/2019
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 07/24/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/24/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/11/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/01/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/17/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/15/2019
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/15/2019
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 04/26/2019
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 04/26/2019
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 04/01/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/29/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/06/2019
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/14/2019
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/13/2019
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 02/08/2019
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/28/2018
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 12/03/2018
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 12/03/2018
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 11/28/2018
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 11/28/2018
Qualigen Therapeutics, Inc. (QLGN) - S-3 SEC Filings 11/21/2018
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 11/09/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/09/2018
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/09/2018
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 11/07/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/06/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/05/2018
Qualigen Therapeutics, Inc. (QLGN) - 4/A SEC Filings 09/19/2018
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 08/20/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 08/15/2018
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/14/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/02/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/27/2018
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 06/27/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/29/2018
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 05/25/2018
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 05/25/2018
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 05/25/2018
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 05/15/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/15/2018
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/15/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/07/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 04/13/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/22/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/19/2018
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 03/19/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/01/2018
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/14/2018
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 02/13/2018
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 01/25/2018
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 01/09/2018
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/20/2017
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 12/01/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/01/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13D/A SEC Filings 11/28/2017
Qualigen Therapeutics, Inc. (QLGN) - PRE 14A SEC Filings 11/07/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13D/A SEC Filings 10/31/2017
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 10/31/2017
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 10/27/2017
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 10/23/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/17/2017
Qualigen Therapeutics, Inc. (QLGN) - S-8 SEC Filings 10/11/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/10/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/04/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 10/03/2017
Qualigen Therapeutics, Inc. (QLGN) - 424B4 SEC Filings 10/02/2017
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 09/29/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1MEF SEC Filings 09/29/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 09/28/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 09/28/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 09/18/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 09/18/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/15/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 09/12/2017
Qualigen Therapeutics, Inc. (QLGN) - FWP SEC Filings 09/11/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 09/07/2017
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 08/25/2017
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 08/09/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 08/08/2017
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/07/2017
Qualigen Therapeutics, Inc. (QLGN) - PRER14A SEC Filings 08/04/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 08/04/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 08/02/2017
Qualigen Therapeutics, Inc. (QLGN) - PRE 14A SEC Filings 07/26/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 07/20/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 07/19/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 07/19/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 07/19/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 07/18/2017
Qualigen Therapeutics, Inc. (QLGN) - FWP SEC Filings 07/18/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 07/17/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 07/14/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 07/03/2017
Qualigen Therapeutics, Inc. (QLGN) - S-8 SEC Filings 06/09/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/09/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/06/2017
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 05/18/2017
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 05/12/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/10/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/09/2017
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 05/09/2017
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/09/2017
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 04/21/2017
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 04/21/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/29/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 03/13/2017
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 02/28/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 02/27/2017
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 02/27/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/15/2017
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 02/14/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/14/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 02/14/2017
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 02/13/2017
Qualigen Therapeutics, Inc. (QLGN) - SC 13G/A SEC Filings 02/10/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 02/10/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 02/09/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 02/09/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 02/06/2017
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 02/01/2017
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 02/01/2017
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 01/27/2017
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 01/24/2017
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 01/17/2017
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/17/2017
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 12/16/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 11/30/2016
Qualigen Therapeutics, Inc. (QLGN) - 3/A SEC Filings 11/15/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 11/07/2016
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/07/2016
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 11/04/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/31/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/27/2016
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 10/27/2016
Qualigen Therapeutics, Inc. (QLGN) - 424B5 SEC Filings 10/26/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/25/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 10/25/2016
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 10/05/2016
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 08/24/2016
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 08/19/2016
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 08/18/2016
Qualigen Therapeutics, Inc. (QLGN) - S-3 SEC Filings 08/11/2016
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/08/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 07/07/2016
Qualigen Therapeutics, Inc. (QLGN) - S-8 SEC Filings 06/16/2016
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 06/08/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 06/06/2016
Qualigen Therapeutics, Inc. (QLGN) - POS AM SEC Filings 06/01/2016
Qualigen Therapeutics, Inc. (QLGN) - POS AM SEC Filings 05/16/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 05/09/2016
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 05/09/2016
Qualigen Therapeutics, Inc. (QLGN) - DEFA14A SEC Filings 04/21/2016
Qualigen Therapeutics, Inc. (QLGN) - DEF 14A SEC Filings 04/21/2016
Qualigen Therapeutics, Inc. (QLGN) - 10-K - Current report SEC Filings 03/21/2016
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 02/25/2016
Qualigen Therapeutics, Inc. (QLGN) - 424B3 SEC Filings 02/25/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 02/24/2016
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 02/12/2016
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 02/09/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 01/29/2016
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 01/19/2016
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 01/19/2016
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 01/12/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 01/11/2016
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 01/08/2016
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 01/05/2016
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 12/31/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 12/21/2015
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 11/10/2015
Qualigen Therapeutics, Inc. (QLGN) - S-8 SEC Filings 10/30/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 10/26/2015
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 10/15/2015
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 09/30/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 09/22/2015
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 08/31/2015
Qualigen Therapeutics, Inc. (QLGN) - 10-Q - Quarterly Report SEC Filings 08/12/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/27/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/14/2015
Qualigen Therapeutics, Inc. (QLGN) - SC 13D SEC Filings 07/10/2015
Qualigen Therapeutics, Inc. (QLGN) - SC 13G SEC Filings 07/01/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-K - Current report SEC Filings 07/01/2015
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 06/30/2015
Qualigen Therapeutics, Inc. (QLGN) - 424B4 SEC Filings 06/26/2015
Qualigen Therapeutics, Inc. (QLGN) - EFFECT SEC Filings 06/25/2015
Qualigen Therapeutics, Inc. (QLGN) - 4 SEC Filings 06/25/2015
Qualigen Therapeutics, Inc. (QLGN) - 3 SEC Filings 06/24/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 06/22/2015
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 06/19/2015
Qualigen Therapeutics, Inc. (QLGN) - FWP SEC Filings 06/19/2015
Qualigen Therapeutics, Inc. (QLGN) - CERTNAS SEC Filings 06/17/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 06/16/2015
Qualigen Therapeutics, Inc. (QLGN) - 8-A12B SEC Filings 06/15/2015
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 06/08/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 06/05/2015
Qualigen Therapeutics, Inc. (QLGN) - FWP SEC Filings 06/04/2015
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 06/02/2015
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 05/22/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 05/21/2015
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 05/20/2015
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 05/08/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 05/08/2015
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 05/07/2015
Qualigen Therapeutics, Inc. (QLGN) - S-1/A SEC Filings 04/24/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 04/24/2015
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 04/07/2015
Qualigen Therapeutics, Inc. (QLGN) - S-1 SEC Filings 03/23/2015
Qualigen Therapeutics, Inc. (QLGN) - CORRESP SEC Filings 03/23/2015
Qualigen Therapeutics, Inc. (QLGN) - UPLOAD SEC Filings 02/26/2015
Qualigen Therapeutics, Inc. (QLGN) - DRS SEC Filings 01/29/2015
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 12/16/2014
Qualigen Therapeutics, Inc. (QLGN) - D/A SEC Filings 11/22/2013
Qualigen Therapeutics, Inc. (QLGN) - D/A SEC Filings 08/07/2012
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 02/23/2012
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 11/30/2010
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 10/12/2010
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 03/19/2010
Qualigen Therapeutics, Inc. (QLGN) - D SEC Filings 08/17/2009
Qualigen Therapeutics, Inc. (QLGN) - REGDEX SEC Filings 03/17/2009

Press Releases

StockPrice Release
Qualigen therapeutics announces $4.5 million private placement of series a-3 convertible preferred stock 07/28/2025
Qualigen granted new patents covering 25 countries 07/16/2025
Qualigen therapeutics, inc. receives expected notification of deficiency from nasdaq related to delayed filing of quarterly report on form 10-q 05/19/2025
Qualigen therapeutics, inc. receives notification of deficiency from nasdaq related to delayed filing of annual report on form 10-k 05/01/2025
Univest securities, llc announces successful closing of $5.1 million private placement for qualigen therapeutics, inc. (nasdaq: qlgn) 11/25/2024
Shares expected to begin trading on split-adjusted basis on november 5, 2024 11/01/2024
Qualigen therapeutics, inc. announces management changes. 09/26/2024
Qualigen therapeutics, inc. received extension from nasdaq hearings panel 09/20/2024
Univest securities, llc announces closing of $3.46 million registered direct offering for its client qualigen therapeutics, inc. (nasdaq: qlgn) 09/06/2024
Qualigen therapeutics, inc. announces closing of $3.47 million public offering 09/06/2024
Qualigen therapeutics, inc. announces pricing of $3.46 million public offering 09/05/2024
Qualigen therapeutics, inc. received nasdaq notice of a delisting determination 05/30/2024
Qualigen therapeutics' novel direct pan-ras inhibitors presented at american association of cancer research (aacr) 2024 annual meeting 04/10/2024
Qualigen therapeutics announces poster featuring positive early clinical experience with qn-302, a novel first-in-class g-quadruplex experimental anti-cancer drug, at the american association of cancer research (aacr) 2024 annual meeting 04/09/2024
Qualigen therapeutics provides corporate update for third quarter and to date 2023 11/14/2023
Qualigen therapeutics announces first patient dosed in the phase 1a clinical trial of qn-302 for treatment of advanced or metastatic solid tumors 11/07/2023
Poster highlighting qualigen therapeutics' pan-ras inhibitor platform presented at aacr special conference: advances in breast cancer 10/23/2023
Qualigen therapeutics presents scientific data on qn-302 at aacr special conference: pancreatic cancer 2023 09/27/2023
Qualigen therapeutics partners with td2 for phase 1 clinical development of qn-302 for the treatment of advanced or metastatic solid tumors 08/17/2023
Qualigen therapeutics, inc. reports financial results and corporate update for quarter ending june 30, 2023 08/15/2023
Qualigen therapeutics announces us fda ind clearance to initiate phase 1 clinical trial of qn-302 for treatment of advanced or metastatic solid tumors 08/01/2023
Qualigen therapeutics divests fastpack® diagnostics business 07/24/2023
Poster highlighting qualigen therapeutics' pan-ras inhibitor platform presented at american society of clinical oncology (asco) 2023 annual meeting 06/05/2023
Qualigen therapeutics, inc. reports fourth quarter and year-end 2022 financial results and provides corporate update 05/02/2023
Qualigen therapeutics' pan-ras inhibitor program highlighted in two abstracts at american society of clinical oncology (asco) 2023 annual meeting 05/02/2023
Qualigen therapeutics, inc. receives nasdaq notice regarding delayed form 10-k filing 04/21/2023
Qualigen therapeutics announces four posters on qn-302 presented at the american association of cancer research (aacr) 2023 annual meeting in orlando, fl 04/18/2023
Qualigen therapeutics presents data on qn-247 in triple negative breast cancer at the american association for cancer research (aacr) annual meeting in orlando, fl 04/18/2023
Composition of matter patent for qn-302 granted by united states patent and trademark office 03/21/2023
Qualigen therapeutics to present five posters at the american association for cancer research annual meeting 2023 03/15/2023
Qualigen therapeutics presents data on its ras inhibitor program at the american association for cancer research: targeting ras conference 03/09/2023
Data on potential biomarker for qualigen therapeutics' lead program qn-302 published in peer-reviewed journal molecules 03/08/2023
Qualigen therapeutics chief executive officer michael poirier provides letter to stockholders 02/01/2023
Qualigen therapeutics initiates good laboratory practice (glp) toxicology studies on qn-302 01/24/2023
Qualigen therapeutics promotes benedict m. abugan to vice president, head of diagnostics and corporate communications 01/23/2023
Qualigen therapeutics receives orphan drug designation from the u.s. food and drug administration for qn-302, a g-quadruplex (g4) transcription inhibitor for the intended indication of pancreatic cancer 01/10/2023
Qualigen therapeutics provides update on developments at nanosynex; significant progress reported on infectious disease diagnostic platform 01/05/2023
Qualigen therapeutics regains compliance with nasdaq minimum bid price rule 12/12/2022
Qualigen therapeutics announces pre-ind feedback from u.s. food and drug administration regarding qn-302 for the treatment of g4-targeted advanced solid tumors 12/07/2022
Qualigen therapeutics, inc. announces 1-for-10 reverse stock split 11/22/2022
Qualigen therapeutics, inc. reports third quarter 2022 financial results and provides corporate update 11/15/2022
Qualigen therapeutics announces two posters of its ras-targeted inhibitor program at the national cancer institute 10/19/2022
Qualigen therapeutics presents data on qn-302 at aacr's pancreatic cancer meeting 09/14/2022
Qualigen therapeutics announces formation and first meeting of qn-302 scientific advisory board 08/18/2022
Qualigen therapeutics, inc. reports second quarter 2022 financial results and provides corporate update 08/16/2022
Qualigen therapeutics reports positive qn-247 readout in triple negative breast cancer in vivo model 08/01/2022
Qualigen therapeutics announces partnership with hande sciences to scale-up manufacturing to support ind-enabling studies for qn-302 07/06/2022
Qualigen therapeutics to present at bio international convention 06/14/2022
Qualigen therapeutics announces ind-enabling studies to advance lead program qn-302 toward clinical trials 06/07/2022
Qualigen therapeutics acquires majority stake in infectious disease diagnostics technology company nanosynex 06/02/2022
Qualigen therapeutics' pan-ras inhibitor featured in two abstracts at american society for clinical oncology (asco) 2022 annual meeting 05/26/2022
Qualigen therapeutics to present at the h.c. wainwright global investment conference 05/20/2022
Qualigen therapeutics, inc. provides corporate update and reports first quarter 2022 financial results 05/13/2022
Qualigen therapeutics' partner nanosynex to present technology at biomed israel 05/10/2022
Qualigen therapeutics to acquire majority stake in diagnostics technology company nanosynex 05/03/2022
Qualigen therapeutics appoints shishir sinha to lead diagnostics division following promotion to senior vice president 04/29/2022
Qualigen therapeutics presents three posters of qn-302 at american association of cancer research conference 04/12/2022
Qualigen therapeutics resumes worldwide distribution and commercial control over fastpack® 04/05/2022
Qualigen therapeutics, inc. reports year-end 2021 financial results 04/01/2022
Qualigen therapeutics engages td2 as contract research organization for preclinical development of qn-302 03/30/2022
Qualigen therapeutics announces three published abstracts at american association of cancer research conference 03/22/2022
Qualigen therapeutics extends research agreement with university of louisville research foundation on ras program 03/15/2022
Qualigen therapeutics ceo michael poirier provides letter to shareholders 02/22/2022
Data from qualigen therapeutics' lead program qn-302 accepted as three poster presentations at aacr 2022 conference 02/15/2022
Qualigen therapeutics engages professor stephen neidle as scientific advisor in the development of lead program qn-302 02/01/2022
Qualigen therapeutics secures worldwide rights to g4-selective transcription inhibitors from university college london to develop as cancer therapeutics 01/18/2022
Qualigen therapeutics promotes amy broidrick to president 12/14/2021
Qualigen therapeutics, inc. announces closing of $8.82 million registered direct offering 12/01/2021
Qualigen therapeutics, inc. announces $8.82 million common stock registered direct offering 11/29/2021
Qualigen therapeutics, inc. reports third quarter 2021 financial results 11/15/2021
Peer-reviewed article confirms that qualigen's fastpack® is as accurate in thyroid stimulating hormone measurement -- and much faster -- than a leading laboratory method 10/19/2021
Qualigen to present at the oppenheimer fall healthcare life sciences & medtech summit 09/15/2021
Qualigen to present at the h.c. wainwright 23rd annual global investment conference 09/08/2021
Qualigen therapeutics, inc. announces submission of investigational new drug (ind) application for qn-165, for the treatment of covid-19 07/14/2021
Qualigen therapeutics announces inclusion in russell microcap® index 06/08/2021
Qualigen therapeutics, inc. to present at the ld micro invitational xi conference 06/02/2021
Qualigen therapeutics, inc. appoints tariq arshad, md, mba as chief medical officer 05/19/2021
Qualigen therapeutics, inc. reports first quarter 2021 financial results and provides corporate update 05/14/2021
Qualigen therapeutics, inc. promotes shishir sinha to chief operating officer position 03/09/2021
Qualigen therapeutics, inc. to present at the oppenheimer 31st annual healthcare conference 03/08/2021
Qualigen therapeutics secures option to negotiate license for g-quadruplex anti-cancer technology from ucl 03/01/2021
Qualigen therapeutics, inc. announces closing of $12 million registered direct offering 12/18/2020
Qualigen therapeutics, inc. announces $12 million registered direct offering 12/16/2020
Qualigen therapeutics completes recertification of existing as1411 drug supply for use in upcoming clinical trials 12/02/2020
Qualigen therapeutics issues ceo letter to stockholders, reports on significant progress and fiscal second quarter financial results 11/13/2020
Qualigen therapeutics posts q1 loss per share of $2.12 08/14/2020
Qualigen signs exclusive license agreement with university of louisville, plans to develop as1411 for treatment of covid-19 06/10/2020
Qualigen therapeutics receives u.s. patent notice of allowance for stars technology 06/04/2020
Ritter pharmaceuticals inc - qtrly loss per share $0.05 03/31/2020
Ritter pharmaceuticals and qualigen announce merger agreement 01/21/2020
Ritter pharmaceuticals inc says on nov 21, co received a letter from nasdaq notifying intentions to delist common stock under listing rule 11/26/2019
Ritter pharmaceuticals reports q3 loss per share $0.23 11/13/2019

More Headlines

News
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel (“Panel”) has granted an extension for the continued listing of the Company, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 19, 2024. The Company is diligently working to fulfill the requirements set forth by the Panel to ensure the Company's continued listing on Nasdaq. 09/20/2024
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of (i) 14,724,058 shares of common stock priced at $0.130 per share, with pre-funded warrants exercisable for 11,972,754 shares with respect to the registered direct offering for its client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. 09/06/2024
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per share with an exercise price of $0.001 per share (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable upon issuance and will remain exercisable until all the Pre-Funded Warrants are exercised in full. 09/06/2024
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at a public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per pre-funded warrant with an exercise price of $0.001 per share (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable upon issuance and will remain exercisable until exercised in full. The closing of the offering is expected to occur on or about September 6, 2024, subject to the satisfaction of customary closing conditions. 09/05/2024
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today? Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%. 07/15/2024
Why Is Qualigen (QLGN) Stock Up 141% Today? Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual interest rate. 07/12/2024
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today? Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more than 59% higher during normal trading hours. 07/08/2024
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company's continued non-compliance with the minimum bid price requirement, pursuant to Listing Rule 5550(b)(2). 05/30/2024
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. 04/10/2024
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. 04/09/2024
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today provides a corporate update for the third quarter ending September 30, 2023 and to date: 11/14/2023
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan. 11/07/2023
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models 10/23/2023
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 Two p osters include data on potential clinical biomarkers and transcriptomic data associated with QN-302's mechanism of action 09/27/2023
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors. 08/17/2023
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack ® diagnostics business for approximately $5 mi llion in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-302 Received US FDA clearance to initiate Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors Presented four posters at the American Association for Cancer Research (AACR) Annual Meeting, in April 2023: “A comparison of the activity of the quadruplex-targeting experimental drugs QN-302 and CX-5461 (Pidnarulex) in wild-type and gemcitabine-resistant pancreatic cancer cell lines” Ahmed Ahmed, Tariq Arshad, and Stephen Neidle (Poster) “The potent quadruplex-binding compound QN-302 down-regulates the S100P gene in vitro and in vivo models of pancreatic cancer: a potential therapeutic target and biomarker for PDAC” Nicole Williams, Jenny Worthington, Ahmed Ahmed, Tariq Arshad, and Stephen Neidle (Poster) “The potent quadruplex-binding compound QN-302 shows anti-tumor activity as a monotherapy in an orthotopic in vivo model of pancreatic cancer” Nicole Williams, Danielle Santos, Jenny Worthington, Ahmed Ahmed, Tariq Arshad and Stephen Neidle (Poster) “Structure-based design rules for potent quadruplex-binding compounds based on the naphthalene diimide core” Stephen Neidle (Poster) Pan-RAS Presented data at the American Society of Clinical Oncology (ASCO) Annual Meeting, in June 2023: “Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines. 08/15/2023
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and d emonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology 08/01/2023
Qualigen Therapeutics Divests FastPack® Diagnostics Business All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeutics 07/24/2023
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. 03/15/2023
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the presentation of two posters… The post Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Progra... 10/19/2022
Qualigen Therapeutics to Present at LD Micro Main Event XV CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Amy Broidrick, President and Chief Strategy Officer, and Tariq Arshad, MD, Chief Medical Officer, will… The post Qualigen Therapeutics to Present at LD Micro Main Event XV appeared first on DKODING... 10/18/2022
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that two abstracts detailing the Company’s RAS-Targeted platform have been accepted to be presented as posters… The post Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourt... 10/06/2022
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic programs and acquisition of majority stake in NanoSynex strengthen Company’s diversified product portfolio CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN),… The post Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate... 08/16/2022
Qualigen Therapeutics to Present at BIO International Convention CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center. 06/14/2022
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL and virtually. 05/20/2022
Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold 05/10/2022
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 04/12/2022
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today? Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket. 04/12/2022
Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR). QN-302 showed potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo metastatic. 04/12/2022
Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022 Check these three Reddit penny stocks out for your watchlist next year The post Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 12/28/2021
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year. 12/27/2021
Best Penny Stocks To Buy This Week? 3 For Your Watch List Here are three penny stocks to watch right now The post Best Penny Stocks To Buy This Week? 3 For Your Watch List appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 12/26/2021
Low Float Penny Stocks To Watch After SOPA Stock Explodes Penny stocks to watch after Society Pass (NASDAQ: SOPA) skyrockets in December. The post Low Float Penny Stocks To Watch After SOPA Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 12/23/2021
Hot Biotech Penny Stocks to Buy Today? 3 For Your December Watchlist Trading biotech penny stocks right now? Check these three out The post Hot Biotech Penny Stocks to Buy Today? 11/30/2021
Hot Penny Stocks to Add to Your Watchlist in December If you're making a penny stocks watchlist for December, check these three out The post Hot Penny Stocks to Add to Your Watchlist in December appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/28/2021
Best Penny Stocks to Buy Right Now? 3 to Watch Next Month Why investors are watching these top penny stocks right now The post Best Penny Stocks to Buy Right Now? 3 to Watch Next Month appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/23/2021
Why Are Qualigen Therapeutics Shares Surging During Premarket Tuesday? Qualigen Therapeutics Inc (NASDAQ:QLGN) shares are trading higher after a Zack's Small Cap research note showed a $9 price target on the stock. The report is based on a probability-adjusted DCF model that considers potential future revenues from QN-247 and RAS-F. 11/23/2021
Qualigen Therapeutics (QLGN) Stock: Why The Price Surged Today The stock price of Qualigen Therapeutics Inc (NASDAQ: QLGN) increased by over 85% pre-market today. This is why it happened. 11/23/2021
Hot Penny Stocks to Buy Right Now? 3 For Your Watchlist Are these penny stocks on your watchlist right now? The post Hot Penny Stocks to Buy Right Now? 11/22/2021
Peer-Reviewed Article Confirms That Qualigen's FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method CARLSBAD, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the publication of a study in the peer-reviewed, open-source journal, Diagnostics, validating the Company's point of care FastPack® IP (“FastPack”) diagnostic test as comparable to an industry-leading laboratory method in determining thyroid stimulating hormone (TSH) levels in blood. 10/19/2021
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021. 09/15/2021
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. 09/08/2021
Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update Tucked in its Q2 earnings release, Qualigen Therapeutics Inc (NASDAQ: QLGN) announced deprioritizing the QN-165 COVID-19 program, sending shares to fall to a 52-week low. In July, the Company filed an FDA Investigational New Drug (IND) application to commence Phase 1b/2a clinical studies with QN-165 in hospitalized COVID-19 patients. 08/17/2021
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19 CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses. 07/14/2021
Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that its CEO and Chairman Michael Poirier will present and participate at the virtual LD Micro Invitational XI Conference, hosted by Sequire Virtual Events, taking place on June 8-10, 2021. 06/02/2021
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs 05/19/2021
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. 05/14/2021
Qualigen Therapeutics Plans to Combat COVID-19 Variants Qualigen Therapeutics Inc (NASDAQ: QLGN) was one of the sponsors for the Benzinga Biotech Global Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. 04/19/2021
Why Is Qualigen Stock Trading Lower Today? Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are ticking lower as the company withdrew the FDA Emergency Use Authorization (EUA) application for its FastPack SARS-CoV-2 IgG diagnostic test for COVID-19 antibodies. According to the SEC filing, the EUA was submitted in June last year, and now the company believes it is no longer viable to launch the test. 04/12/2021
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announced today that it has promoted long-time officer Shishir Sinha to the newly created position of Chief Operating Officer. Mr. Sinha is based in Qualigen's corporate headquarters in Carlsbad, California. 03/09/2021
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen, will present at the Oppenheimer 31st Annual Healthcare Conference being held March 16-18 2021. 03/08/2021
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today it has entered into a Material Evaluation and Option Agreement with the University College London (UCL) to advance development of and potentially expand toward future commercial uses of Qualigen's leading anticancer drug candidate AS1411-GNP, also known as ALAN (Aptamer-Linked Anti-Nucleolin). 03/01/2021
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of common... 12/18/2020
Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formulation and filling for use in the Company's proposed Phase 2a efficacy trials of AS1411 for the... 12/02/2020

Unlock

QLGN Ratings Summary

QLGN Quant Ranking